Feb 03, 2021
The Board of Directors of Sedia Biosciences Corporation today announced a series of changes to the Company's executive management team.
Jul 30, 2020
Expansion accommodates significant growth in demand for its new rapid point-of-care HIV tests intended to break the chain of new HIV infections worldwide
Jul 17, 2013
Strategic China partner to aid in access to new international markets for the company’s epidemiological and diagnostic products.
May 20, 2013
The Sedia™ HIV-1 Limiting Antigen Avidity Enzyme Immunoassay, a powerful new tool in the global fight against HIV, measures the maturation of the immune response to identify recent HIV infections among those already identified as positive.
Jul 19, 2012
Phase I funding of the competitive grant is to develop a novel commercial assay to measure host HIV antibody avidity ("binding ability"), an indicator of antibody maturation, which can be used to determine recent vs. long-term HIV-1 infections.
Sep 30, 2009
SEDIA launches its SEDIA™ Dried Blood Spot Controls Pack, a controls and calibrator pack that enables expanded use of the SEDIA™ BED HIV-1 Incidence EIA using dried blood spot specimens for population estimates of HIV-1 incidence.
Aug 18, 2009
SEDIA launches its SEDIA(TM) BED HIV-1 Incidence EIA, an enzyme immunoassay based on technology licensed from the US CDC for population estimates of HIV-1 incidence